A pharmaceutical business's regulatory affairs (RA) department is in charge of getting clearance for new pharmaceutical goods and ensuring that approval is maintained for as long as the business wants the product to be on the market. It acts as a liaison between the regulatory authority and the project team, as well as a channel of communication with the regulatory authority as the project progresses, with the goal of ensuring that the project plan accurately anticipates the regulatory authority's requirements before the product is approved. RA is responsible for staying up to date on new legislation, rules, and other regulatory information. In the creation, inspection, quality assurance, and safety assessment of new and current consumable, medicinal, and diagnostic products, regulatory affairs is a mandatory and necessary effort (both ethically and regulatorily).
Title : Copper (II) complexes as potential anticancer agents
Salah S Massoud, University of Louisiana, United States
Title : Pharmacogenomics: current status and future directions
Matthias Schwab, University of Tübingen, Germany
Title : Talus bone of the hindfoot: Unique anatomy and an important clinical implication
Abdelmonem Awad Hegazy, Zarqa University, Jordan
Title : The use of anti seizure medication therapeutic blood level determination to personalise the treatment of epileptic seizures especially in patients attending the accident and emergency department
Roy Gary Beran, University of New South Wales, Australia
Title : Effect of Fluvoxamine on Interluekin-6 level of COVID-19 patients, hospitalized in ICU: A randomized clinical trial
Mitra Safa, Shahid Beheshti University of Medical Sciences, Iran (Islamic Republic of)
Title : Precision Treatment of Alzheimer's
Boris Tankhilevich, Magtera, Inc., United States